Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Science

11 Aug 2023

New Study Compares Psychedelics to Hypnosis and Meditation

A new study explores what happens in the brain while under the influence of psychedelics, meditation, and hypnosis....

By Jason Najum

Breaking News

10 Aug 2023

Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program

Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound....

By Jason Najum

Industry

2 Aug 2023

Awakn Life Sciences Completes Sale of Clinics; Shifts To Biotech Development

Awakn Life Sciences has sold its last clinic and shifted its focus entirely to its clinical trials and biotech research....

By Jason Najum

Industry

26 Jul 2023

Wonderland Expands: Bringing Together Psychedelics, Mental Health, & Longevity

Microdose’s Wonderland conference is the premier industry event in the psychedelic medicine space - and now it's expanding into mental health and longevity....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Culture

19 Jul 2023

The World’s First Functional Music Record Label: An Interview With Paul Nolan

Microdose Music and Paul Nolan are launching a new psychedelic album and functional music record label....

By Jason Najum

Law & Politics

12 Jul 2023

Police Raid Montreal Mushroom Dispensary on Opening Day

Montreal police raid leads to 4 arrests on opening day of Quebec's first magic mushroom shop...

By Jason Najum

Law & Politics

11 Jul 2023

Australia Legalizes Psychedelics: Are the US and Canada Next?

Australia has legalized psychedelic therapy, could either Canada or the USA be next to legalize medical psilocybin and MDMA?...

By Jason Najum

Finance

4 Jul 2023

The Commercial Market for Legal Psychedelics: Spravato

Spravato provides insights into market potential of legal psychedelics - we take a closer look....

By Jason Najum
psychedelic markets

Finance

29 Jun 2023

Small Pharma Reports 2023 Financial Results & Business Highlights

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights...

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.